{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:57:45Z","timestamp":1791575865618,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Royal Library, Copenhagen University Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40264-023-01317-0","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:01:47Z","timestamp":1686355307000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data"],"prefix":"10.1007","volume":"46","author":[{"given":"Fahed","family":"Al-Azzawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Haguinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"key":"1317_CR1","unstructured":"Medicines Agency E. Guideline on good pharmacovigilance practices (GVP) Module IX_Signal management (Rev 1) Date of coming into effect of first version. EMA Web Page. 2017. p. 1\u201312."},{"key":"1317_CR2","unstructured":"European Medicine Agency. 2020 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission. 2020 [cited 2022 Feb 17]; EMA Web Page2. 2022. p. 1\u2013100."},{"key":"1317_CR3","unstructured":"European Medicine Agency. Validation of signals from the review of individual cases. EMA Web Page. 2009. p. 1\u201310."},{"key":"1317_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1317_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43:479\u201387.","journal-title":"Drug Saf"},{"key":"1317_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.tips.2021.09.007","volume":"42","author":"A Bate","year":"2021","unstructured":"Bate A, Stegmann J-U. Safety of medicines and vaccines\u2013building next generation capability. Trends Pharmacol Sci Elsevier. 2021;42:1051\u201363.","journal-title":"Trends Pharmacol Sci. Elsevier"},{"key":"1317_CR7","unstructured":"WHO. ATC classification. WHO website. 2022."},{"key":"1317_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/pds.3529","volume":"23","author":"F Maignen","year":"2014","unstructured":"Maignen F, Hauben M, Hung E, Van Holle L, Dogne J-M. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiol Drug Saf England. 2014;23:195\u2013207.","journal-title":"Pharmacoepidemiol Drug Saf England"},{"key":"1317_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","volume":"316","author":"DN Kyriacou","year":"2016","unstructured":"Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA US. 2016;316:1818\u20139.","journal-title":"JAMA US"},{"key":"1317_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"211","author":"T de Vries","year":"2020","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211: 107528.","journal-title":"Pharmacol Ther"},{"key":"1317_CR11","first-page":"243","volume":"97","author":"L Mayans","year":"2018","unstructured":"Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97:243\u201351.","journal-title":"Am Fam Physician"},{"key":"1317_CR12","doi-asserted-by":"crossref","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. SAGE Publications Sage CA: Los Angeles, CA; 2008;42:409\u201319.","DOI":"10.1177\/009286150804200501"},{"key":"1317_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jamia\/ocv153","volume":"23","author":"TA Kass-Hout","year":"2016","unstructured":"Kass-Hout TA, Xu Z, Mohebbi M, Nelsen H, Baker A, Levine J, et al. OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data. J Am Med Informatics Assoc. 2016;23:596\u2013600.","journal-title":"J Am Med Informatics Assoc"},{"key":"1317_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AFZ Wisniewski","year":"2016","unstructured":"Wisniewski AFZ, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf New Zealand. 2016;39:469\u201390.","journal-title":"Drug Saf. New Zealand"},{"key":"1317_CR15","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","volume":"314","author":"JS Haukoos","year":"2015","unstructured":"Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314:1637\u20138.","journal-title":"JAMA"},{"key":"1317_CR16","doi-asserted-by":"crossref","unstructured":"Meredith M, Ridout M. Overlap: estimates of coefficient of overlapping for animal activity patterns. R Packag version 02. 2014;4.","DOI":"10.32614\/CRAN.package.overlap"},{"key":"1317_CR17","unstructured":"Guideline on the use of statistical signal detection methods on the EudraVigilance data anlysis system. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/11\/WC500011437.pdf."},{"key":"1317_CR18","first-page":"3905","volume":"16","author":"T Hothorn","year":"2015","unstructured":"Hothorn T, Zeileis A. partykit: A modular toolkit for recursive partytioning in R. J Mach Learn Res JMLR org. 2015;16:3905\u20139.","journal-title":"J Mach Learn Res. JMLR. org"},{"key":"1317_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-6849-3","volume-title":"Applied predictive modeling","author":"M Kuhn","year":"2013","unstructured":"Kuhn M, Johnson K. Applied predictive modeling. Berlin: Springer; 2013."},{"key":"1317_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14740338.2016.1221397","volume":"15","author":"M Sessa","year":"2016","unstructured":"Sessa M, Rafaniello C, Sportiello L, Mascolo A, Scavone C, Maccariello A, et al. Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. Expert Opin Drug Saf England. 2016;15:9\u201315.","journal-title":"Expert Opin Drug Saf. England"},{"key":"1317_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/0976-500X.184777","volume":"2","author":"M Sessa","year":"2016","unstructured":"Sessa M, Sullo MG, Mascolo A, Cimmaruta D, Romano F, Puca RV, et al. A case of figurate urticaria by etanercept. J Pharmacol Pharmacother. 2016;2:106\u20138.","journal-title":"J Pharmacol Pharmacother"},{"key":"1317_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2017.00305","volume":"8","author":"M Sessa","year":"2017","unstructured":"Sessa M, Sportiello L, Mascolo A, Scavone C, Gallipoli S, di Mauro G, et al. Campania Preventability Assessment Committee (Italy): a focus on the preventability of non-steroidal anti-inflammatory drugs\u2019 adverse drug reactions. Front Pharmacol. 2017;8:305.","journal-title":"Front Pharmacol"},{"key":"1317_CR23","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.1038\/s41598-019-43715-4","volume":"9","author":"M Sessa","year":"2019","unstructured":"Sessa M, Mascolo A, Callr\u00e9us T, Capuano A, Rossi F, Andersen M. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(\u00ae). Sci Rep. 2019;9:7236.","journal-title":"Sci Rep"},{"key":"1317_CR24","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1517\/14740338.2015.1067301","volume":"14","author":"M Sessa","year":"2015","unstructured":"Sessa M, Rossi C, Mascolo A, Grassi E, Fiorentino S, Scavone C, et al. Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance. Expert Opin Drug Saf England. 2015;14:1341\u201351.","journal-title":"Expert Opin Drug Saf. England"},{"key":"1317_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14740338.2016.1226280","volume":"15","author":"M Sessa","year":"2016","unstructured":"Sessa M, Rossi C, Rafaniello C, Mascolo A, Cimmaruta D, Scavone C, et al. Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions. Expert Opin Drug Saf Engl. 2016;15:51\u20139.","journal-title":"Expert Opin Drug Saf Engl"},{"key":"1317_CR26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/978-1-4613-9655-0_2","volume-title":"The bivariate normal distribution. Multivar Norm Distrib","author":"YL Tong","year":"1990","unstructured":"Tong YL, Tong YL. The bivariate normal distribution. Multivar Norm Distrib. Berlin: Springer; 1990. p. 6\u201322."},{"key":"1317_CR27","doi-asserted-by":"crossref","unstructured":"Tian S, Qin D, Zhou Y. Genetic data generation method based on multivariate binary random variables. Proc 6th Int Conf Comput Sci Appl Eng. 2022. p. 1\u20135.","DOI":"10.1145\/3565387.3565408"},{"key":"1317_CR28","doi-asserted-by":"crossref","unstructured":"Sessa M, Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs. New Zealand; 2021;","DOI":"10.1007\/s40259-021-00469-8"},{"key":"1317_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4161\/hv.9216","volume":"5","author":"Z Zeinoun","year":"2009","unstructured":"Zeinoun Z, Seifert H, Verstraeten T. Quantitative signal detection for vaccines: effects of stratification, background and masking on GlaxoSmithKline\u2019s spontaneous reports database. Hum Vaccin. 2009;5:599\u2013607.","journal-title":"Hum Vaccin"},{"key":"1317_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","volume":"25","author":"A Bate","year":"2002","unstructured":"Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25:393\u20137.","journal-title":"Drug Saf"},{"key":"1317_CR31","unstructured":"Agency EM. Screening for adverse reactions in EudraVigilance. EMA\/849944\/2016. 2016;3\u201333."},{"key":"1317_CR32","unstructured":"Topamax (Topiramate): uses, dosage, side effects, interactions, warning."},{"key":"1317_CR33","unstructured":"Levate (amitriptyline), dosing, indications, interactions, adverse effects, and more."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01317-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01317-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01317-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T21:55:21Z","timestamp":1729547721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01317-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01317-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"7 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS and FA had the idea for the project. All authors drafted and commented on the manuscript. FA performed data management and analysis. MS developed the framework. All authors read and approved the final version of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest in this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We used publicly available data from FAERS that can be accessed at:\n                      \n                      . The code of our simulations is provided in ESM 1.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Code availability can be requested upon reasonable request to the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}